Payment overview · 2025
General Payments
$934.25
46 reported records · 18 companies
Healthcare provider profile · identity verified
Christopher E Salem, DO
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · IRVINE, CA · NPI 1124273313
Verified facts
What the public records show
CMS Open Payments records show Christopher E Salem, DO received $934.25 in general payments during 2025 across 46 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 538 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 538 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $166.44 | 17.8% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.20 | 15.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.92 | 9.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.29 | 8.7% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $72.22 | 7.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.61 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.38 | 4.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.21 | 4.7% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $33.33 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.35 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.39 | 3.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.93 | 3.1% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 2.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.75 | 2.3% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.55 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.10 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.26 | 2.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.13 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $891.75 | 45 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $166.44 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.20 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $83.92 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.92 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.29 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $72.22 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $61.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.38 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.93 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 538 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
538 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
538 | 69 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1058 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 854 | 160 |
| Metformin Hcl | Metformin Hcl | 574 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 101 |
| Eliquis | Apixaban | 538 | 69 |
| Gabapentin | Gabapentin | 519 | 103 |
| Lisinopril | Lisinopril | 501 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 445 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 426 | 87 |
| Losartan Potassium | Losartan Potassium | 424 | 88 |
| Famotidine | Famotidine | 389 | 69 |
| Quetiapine Fumarate | Quetiapine Fumarate | 366 | 61 |
| Furosemide | Furosemide | 327 | 74 |
| Trazodone Hcl | Trazodone Hcl | 270 | 51 |
| Donepezil Hcl | Donepezil Hcl | 260 | 40 |
| Omeprazole | Omeprazole | 260 | 55 |
| Memantine Hcl | Memantine Hcl | 251 | 40 |
| Baclofen | Baclofen | 246 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 43 |
| Glipizide | Glipizide | 221 | 38 |
| Levetiracetam | Levetiracetam | 219 | 33 |
| Potassium Chloride | Potassium Chloride | 198 | 43 |
| Carvedilol | Carvedilol | 197 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 31 |
| Mirtazapine | Mirtazapine | 183 | 41 |
| Divalproex Sodium | Divalproex Sodium | 182 | 26 |
| Simvastatin | Simvastatin | 179 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 41 |
| Risperidone | Risperidone | 171 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 36 |
| Jardiance | Empagliflozin | 155 | 27 |
| Ibuprofen | Ibuprofen | 141 | 49 |
| Dexlansoprazole Dr | Dexlansoprazole | 138 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 24 |
| Olanzapine | Olanzapine | 133 | 22 |
| Clonidine Hcl | Clonidine Hcl | 126 | 36 |
| Finasteride | Finasteride | 125 | 28 |
| Alendronate Sodium | Alendronate Sodium | 118 | 24 |
| Vascepa | Icosapent Ethyl | 115 | 17 |
| Lorazepam | Lorazepam | 113 | 36 |
| Sertraline Hcl | Sertraline Hcl | 112 | 29 |
| Xarelto | Rivaroxaban | 112 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 22 |
| Lactulose | Lactulose | 111 | 26 |
| Pregabalin | Pregabalin | 103 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 20 |
| Buspirone Hcl | Buspirone Hcl | 96 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 39 |
| Januvia | Sitagliptin Phosphate | 92 | suppressed |
| Latanoprost | Latanoprost | 90 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 35 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 24 |
| Ozempic | Semaglutide | 86 | 15 |
| Allopurinol | Allopurinol | 85 | 24 |
| Benazepril Hcl | Benazepril Hcl | 85 | 19 |
| Humulin R | Insulin Regular, Human | 85 | 21 |
| Gemfibrozil | Gemfibrozil | 83 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 83 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | suppressed |
| Meloxicam | Meloxicam | 77 | 17 |
| Spironolactone | Spironolactone | 77 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 76 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 12 |
| Azithromycin | Azithromycin | 71 | 59 |
| Atenolol | Atenolol | 69 | 13 |
| Lidocaine | Lidocaine | 69 | 18 |
| Digoxin | Digoxin | 64 | suppressed |
| Methocarbamol | Methocarbamol | 64 | 18 |
| Montelukast Sodium | Montelukast Sodium | 62 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Prednisone | Prednisone | 59 | 21 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 58 | suppressed |
| Aripiprazole | Aripiprazole | 57 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 46 |
| Entresto | Sacubitril/Valsartan | 53 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 53 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 30 |
| Enoxaparin Sodium | Enoxaparin Sodium | 51 | 13 |
| Tramadol Hcl | Tramadol Hcl | 50 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 18 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | 11 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 11 |
| Meclizine Hcl | Meclizine Hcl | 47 | 14 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 45 | 17 |
| Naproxen | Naproxen | 45 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Lubiprostone | Lubiprostone | 42 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Alogliptin | Alogliptin Benzoate | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 14 |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Paliperidone Er | Paliperidone | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 18 |
| Linzess | Linaclotide | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 17 |
| Valproic Acid | Valproic Acid | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 31 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Clozapine | Clozapine | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Bethanechol Chloride | Bethanechol Chloride | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 24 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Phenytoin | Phenytoin | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Loperamide | Loperamide Hcl | 22 | 19 |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Neomycin Sulfate | Neomycin Sulfate | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | 11 |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Permethrin | Permethrin | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | 12 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Nystop | Nystatin | 13 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Embrace Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $934.25 · 46 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AFREZZA, AIRSUPRA, APLIGRAF, AUSTEDO XR, AZMIRO, CAPLYTA, COBENFY, CONTRAVE, ELIQUIS, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Paradise Ultrasound Renal Denervation System, REPATHA, REXULTI, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error